Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | GALK1 | P51570 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26327709 | 0.88 | NR1H2 (0.36) | NR1H2NR1H3GALK1CYP1A2CYP2C19 | |
| SCHEMBL20565012 | 0.80 | TAS1R3 (0.40) | PPARGPPARDPPARAKDM4EALDH1A1 | |
| SCHEMBL20564998 | 0.78 | LMNA (0.32) | PPARGPPARDPPARAKDM4E | |
| SCHEMBL26324906 | 0.77 | PPARG (0.34) | PPARGPPARDPPARACYP1A2CYP2C19 | |
| SCHEMBL25439960 | 0.76 | HDAC3 (0.33) | ALDH1A1 | |
| SCHEMBL20564580 | 0.75 | CHRNB2 (0.39) | PPARGPPARDPPARASMN1; SMN2ALDH1A1 | |
| SCHEMBL25440212 | 0.75 | HDAC1 (0.40) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL25440228 | 0.72 | ESR1 (0.41) | CYP1A2CYP2C19SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL25439783 | 0.71 | RAB9A (0.35) | PPARGPPARDPPARAALDH1A1 | |
| SCHEMBL25440275 | 0.69 | NPC1 (0.40) | PPARGPPARASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2018213572-A9 | PREPARATION OF SECONDARY AMINES WITH ELECTROPHILIC N-LINCHPIN REAGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018213572-A1 | PREPARATION OF SECONDARY AMINES WITH ELECTROPHILIC N-LINCHPIN REAGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | PNMT, NCL, NPM1 | NR1H2 3952/4885NR1H3 3551/4885PPARG 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.